Issue 31, 2023

Visible light-activatable platinum(iv) prodrugs harnessing CD36 for ovarian cancer therapy

Abstract

We hereby engineered photoactivatable Pt(IV) metallodrugs that harness CD36 to target ovarian cancer cells. Pt(IV) compounds mimic the structure of fatty acids and take advantage of CD36 as a “Trojan horse” to gain entry into the cells. We confirmed that CD36-dependent entry occurs using graphite furnace atomic absorption spectroscopy with ovarian cancer cells expressing different levels of CD36 and a CD36 inhibitor, SSO. Once the Pt(IV) metallodrugs enter the cancer cells, they can be activated to form Pt(II) with characteristics of cisplatin under visible light (490 nm) irradiation, promoting photoinduced electron transfer from the attached fluorophore to the metal center. This light-induced activation can increase the cytotoxicity of the Pt(IV) metallodrugs by up to 20 times toward ovarian cancer cells, inducing DNA damage and enabling efficient elimination of drug-resistant cancer cells.

Graphical abstract: Visible light-activatable platinum(iv) prodrugs harnessing CD36 for ovarian cancer therapy

Supplementary files

Article information

Article type
Paper
Submitted
30 Apr 2023
Accepted
05 Jul 2023
First published
12 Jul 2023

Dalton Trans., 2023,52, 10942-10950

Author version available

Visible light-activatable platinum(IV) prodrugs harnessing CD36 for ovarian cancer therapy

A. M. D. S. Jayawardhana, S. Bhandari, A. W. Kaspi-Kaneti, M. Kshetri, Z. Qiu, M. Cheline, H. Shen, B. D. Dunietz and Y. Zheng, Dalton Trans., 2023, 52, 10942 DOI: 10.1039/D3DT01292A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements